Dose-Dense Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Node-Positive Breast Cancer
| Autor: | Parastoo Hajian, Sepideh Jafari Naeini, Pegah Bikdeli, Ladan Mohammadi Yeganeh, Hamid Reza Mirzaei, Fatemeh Nasrollahi |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Oncology
medicine.medical_specialty Article Subject Anthracycline Cyclophosphamide business.industry General Medicine medicine.disease Surgery Regimen chemistry.chemical_compound Breast cancer Paclitaxel chemistry Internal medicine Clinical Study medicine Adverse effect business Pegfilgrastim Epirubicin medicine.drug |
| Zdroj: | Chemotherapy Research and Practice |
| ISSN: | 2090-2115 2090-2107 |
| DOI: | 10.1155/2014/259312 |
| Popis: | Background. Adding taxanes to anthracycline-based adjuvant chemotherapy has shown significant improvement in node-positive breast cancer patients but the optimal dose schedule has still remained undetermined. Objectives. The feasibility of dose-dense epirubicin in combination with cyclophosphamide (EC) followed by weekly paclitaxel as adjuvant chemotherapy in node-positive breast cancer patients was investigated. Methods. All patients were treated with epirubicin (100 mg/m2) and cyclophosphamide (600 mg/m2) every two weeks for four cycles with daily Pegfilgrastim (G-CSF) that was administered 3–10 days after each cycle of epirubicin and cyclophosphamide infusion which followed by (80 mg/m2) paclitaxel for twelve consecutive weeks. Results. Sixty consecutive patients were analyzed, of whom 57 patients (95%) completed the regimen and no case of toxicity-related death was observed. Grade 3/4 hematologic toxicity was uncommon and the most common grade 3/4 nonhematological adverse event was neuropathy disorders. Conclusions. Dose-dense epirubicin and cyclophosphamide followed by weekly paclitaxel with G-CSF support is a well-tolerated and feasible regimen in node-positive breast cancer patients without serious complications. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|